Table 2B.
The association of key clinical outcome measures with autoantibody subgroups.
| Lowest ever CMASa median (IQR) | Highest ever PGAb median (IQR) | Ever received biologic drug (%) | Ever received IV cyclophosphamide (%) | |
|---|---|---|---|---|
| Total cohort (n = 379)c | 40 (24.5–47.5) | 4 (2.2–7.0) | 77 (20) | 89 (23) |
| Anti-TIF1γ (n = 68) |
40 (25–47)** | 5.2 (2.6–7.6) | 23 (34)** | 25 (37)* |
| Anti-NXP2 (n = 59) |
29.5 (16–43)*** | 4.6 (2.7–6.9) | 11 (19) | 10 (17) |
| Anti-MDA5 (n = 23) |
45 (38–52)*** | 4.1 (3.1–6.7) | 1 (4) | 6 (26) |
| Anti-PmScl (n = 20) |
45.5 (22–49) | 3 (1.5–6.9) | 3 (15) | 5 (25) |
| Anti- Mi2 (n = 15) |
29 (15–38)*** | 4.8 (2.45–7) | 1 (7) | 3 (20) |
| Anti-U1RNP (n = 14) |
46.5 (42–49)*** | 3.4 (1–5.2) | 2 (14) | 1 (7) |
| Anti-SRP (n = 7) |
26 (9.8–42)*** | 6.6 (3.5–6.9) | 2 (29) | 2 (29) |
| Anti-synthetased (n = 6) |
44.5 (41–48) | 3.3 (2.4–5.5) | 1 (17) | 2 (33) |
| Anti-HMGCR (n = 4) |
15 (1–30)*** | 6.6 (4.4–8.6) | 4 (100) | 2 (50) |
| Anti-SAE (n = 3) |
39 (23–47) | 3.5 (2–7) | 0 | 0 |
| Othere (n = 5) |
40 (25–47)** | 4.1 (2.3–7) | 2 (40) | 1 (20) |
| Nil identifiedf (n = 155) |
43 (27–48) | 3.2 (2.0–6.0) | 28 (18) | 32 (21) |
Statistically significant associations are highlighted in bold.
*P < 0.05, **P < 0.01, ***P < 0.001, PM; polymyositis.
CMAS; Childhood Myositis Assessment Score, PGA; Physician Global Assessment of disease activity.
a
Data available for 355 patients.
b
Data available for 370 patients.
c
Including 8 patients with other idiopathic inflammatory myopathy.
d
3 patients anti-Jo-1, 2 patients anti-PL12 and 1 patient anti-PL7.
e
1 anti-Ku, 1 anti-Scl70, 1 anti-Ro60, 1 anti-U3RNP, 1 anti-mitochondrial antibody.
f
No known autoantibody identified using the techniques described (42% of this group have unidentified bands visible on immunoprecipitation).